Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

LG Chem discovers new enteropeptidase inhibitors

Nov. 28, 2019

Loss-of-function allele in SLC30A8 improves insulin secretion and protects from type 2 diabetes

Nov. 27, 2019

Janssen Pharmaceutica presents dual SGLT1 and SGLT2 inhibitors

Nov. 27, 2019

Poxel reports topline data from TIMES 3 open-label extension of imeglimin in type 2 diabetes

Nov. 26, 2019

AKCEA-TTR-LRx begins phase III trial for polyneuropathy caused by hATTR amyloidosis

Nov. 25, 2019

Clinical data presented for AT-001 in patients with T2D-derived diabetic cardiomyopathy

Nov. 25, 2019

Neuraly studies NLY-01 in phase II for type 2 diabetes

Nov. 25, 2019

Hepatic YBX1 as a novel therapeutic target for obesity-related liver disorders

Nov. 25, 2019

First-in-human study of AZD-2693

Nov. 22, 2019

FDA approves Givlaari for acute hepatic porphyria

Nov. 21, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...